BioSpace News Archive

Finalizing preparations for pharmacokinetic (PK) clinical trials of AQST-108 First planned PK clinical trial expected to begin during the third quarter of 2020 WARREN, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast T

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced it will host a conference call on Friday, August 14 , at 8:30 a.m. Eastern time to discuss its financial and operating results for the second quarter 2020,

Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), today announced financial and business results for its Second Quarter Fiscal Year 2020 ended June 30, 2020. Q2 2020 net loss was $1.8 million, or $0.45 per share, including payments to NanoTx LLC of $0.78 million. Net cash used in operating activities for the six months ended June 30, 2020 was approximately $2.9 million. Plus Therapeutics ended Q2 2020 with approximately $9.3 million

Recently Reported Preliminary First-Half 2020 Sales Were x3 Higher than Same Period in 2019, Demonstrating Significant Growth as Cryoablation Technology Continues to Gain Global Awareness

Boehringer Ingelheim today announced a new analysis from the GioTag study, which showed that sequential Gilotrif® (afatinib) and osimertinib contributed to a median overall survival (OS) of nearly four years (47.6 months) among U.S. patients (129) with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC) and the common resistance mutation, T790M

Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, announced that its 2020 Annual Meeting of Stockholders that convened on August 7, 2020 has been adjourned until September 4, 2020 at 2:00 p.m. Eastern Time

Novocellbio Co., Ltd. conducted experiments using “NOVO-NK”, an autologous natural killer cell treatment at Seoul National University College of Medicine. It was confirmed that the autologous natural killer cell treatment agent NOVO-NK killed the human-derived COVID-19 coronavirus.

Certara®, the global leader in biosimulation, today announced the development of a new biosimulation platform for COVID-19 vaccines and major enhancements in its Immunogenicity and Immuno-oncology QSP platforms. Certara has partnered with leading, global pharmaceutical companies on these advancements

Received U.S. FDA Approval of Jelmyto ® , the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) Successfully Commenced Launch of Jelmyto on June 1 st as Planned; Initial Commercial Performance Demonstrates Strong Execution Announced Positive Complete Response and Durability Data of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC); On

The company announced that the Brazilian regulatory agency, Anvisa, has granted permission to commence a Phase III study of lenzilumab in patients with COVID-19 in Brazil.